We analyzed mononuclear leukocytes from patients with various human leukemias by high-resolution two-dimensional electrophoresis. Tumor cells of the granulocytic, monocytic, and lymphoid lineages [obtained from chronic granulocytic leukemia in blast transformation, acute monocytic leukemia, and chronic lymphocytic leukemia (CLL), respectively] can be easily recognized by using a series of cell-type marker proteins identified by comparison of fractionated normal cell populations. B and T cell types of CLL could be distinguished, the results correlating well with those obtained by use of monoclonal-antibody staining methods. In two cases representing almost pure B-cells (classical CLL; 0% T, 85% B) and T-cells (cutaneous T-cefl leukemia; 77% T, 0% B), 27 of 29 marker proteins showed quantitative B/T differences comparable to those observed in comparisons of normal Band T-lymphocytes prepared by cell sorting. These results indicate that cells from relatively well-differentiated leukemias show complex patterns of gene expression very similar to those of the corresponding normal cells and strongly support the use of large marker panels in cell-type determination. Less-well-differentiated acute leukemias [such as acute undifferentiated and acute granulocytic (FAB:M1)] appear to yield protein patterns corresponding less closely to recognizable mature cell types, and may show expression of novel proteins related to the state of differentiation.
The human peripheral blood leukocytes constitute a nearly ideal system for exploring the usefulness of such a protein-cataloging approach. The cells are easily obtained in a viable state, and can be cultured in vitro for extended periods of time. Numerous studies have begun to identify important leukocyte gene-regulation systems Iheat shock (5), interferon (6), mitochondnal inhibitors (7), phorbol ester tumor promoters (6)1, and to determine the physical locations of particular proteins within the cell [e.g., mitochondna (7), cytoskeleton greater precision. However, these techniques also demonstrate clearly the fragmentary nature of present knowledge and argue strongly that even more (and better) markers will be necessary to characterize the variety of cells observed. The motivation for the development of objective markers for all cell types and differentiation stages is not academic; even the classification of acute leukemias into three lymphoblastic and six nonlymphoblastic categories in the FrenchAmerican-British (FAB) system can, when applied by different pathologists, give rise to differing initial diagnoses in 30 to 40% of patients (12) . A more exact and objective method of classification is thus highly desirable.
In this paper we report some results obtained in a pilot study of leukocytes obtained from leukemia patients. Our major objectives were to identify technical difficulties and, given some technical success, to begin to assess the usefulness of the high-resolution two-dimensional electrophoretic mapping approach in the study of various forms of leukemia. The results indicate that a systematic examination of the leukemias is feasible and justified.
Materials and Methods

Leukemic leukocyte specimens.
Blood specimens from patients with leukocyte counts exceeding 15 000 per microliter or with known hematologic diseases were obtained from the Mayo Clinic central processing or hematology laboratories within 1 to 5 h of venipuncture.
Patients were identified by a serial number within the study, prefixed by the letter Z. (4, 5) . After this solubilization, samples were centrifuged for 1 mm in the Microfuge to pellet nuclear DNA, frozen at -80 #{176}C, and transported to Argonne on solid CO2.
Two-dimensional electrophoresis and computer analysis.
Samples were analyzed by using the 18 x 18 cm ISO-DALT system as previously described (2, 3, 13) . In general, a 20-L sample containing labeled proteins from -600 000 leukoCytes (-40 g of protein) was applied to each gel. Isoelectric focusing was performed in 40-place tube gel devices, and SDS-electrophoresis by using slab gels cast in batches of 20 and run 10 gels per DALT tank. Gels were stained with Coomassie Blue, destained, dried, and autoradiographed on Kodak X.AR-2 film. Selected films were scanned and processed in the TYCHO system as previously described (4).
Quantitation of T-and B-cells in CLL samples.
Blood smears were made from the blood specimens to be processed for study. T and B lymphocytes on th smears were identified by use of an indirect immuno-alkaline phosphatase "stain" involving monoclonal antibodies specific for T cellsurface antigen and HLA-DR 
Results
Cell-Type-Specific Marker Proteins in Leukemia
We examined peripheral leukocytes from patients with chronic granulocytic leukemia (CGL), acute monocytic leukemia, and chronic lymphocytic leukemia (CLL) for the presence of characteristic marker proteins that had been identified in studies of corresponding normal cells (9) . The principal granulocyte markers (G:1-4) are strongly expressed in mononuclear cells from a CGL patient ( Figure  l#{192} ), but not in normals or in the other leukemias examined. These cells also show several major uncommon proteins (Q:4 for example, perhaps associated with the numerous eosinophils or basophils). The major monocytic marker proteins (M:1, 2, 8-11 and Mitcon:5) are likewise strongly expressed in the peripheral blood cells (mostly blasts) obtained in a case of acute monocytic leukemia ( Figure 1C ), but not in normal or non-monocytic leukemic leukocytes. Several other proteins are apparent (typified by Q:5 and Q:6 in panel C, and the Q:7 complex identified in Figure 3 ) that were not previously seen in either normal monocytes or macrophages. Both the CGL and the acute monocytic leukemia show strong expression of Calgon: 1, a marker shared by normal granulocytes and monocytes. Peripheral blood cells from CLL patients ( Figure 1E and 2) yield patterns rather similar to normal lymphocytes if the lymphocyte subtype differences are taken into account (cells usually show an abundance of B-cell markers B:1, -2, and -5, owing to the more common occurrence of B-CLL).
T-and B-Lymphocyte Markers in CLL
By making use of enzyme-labeled monoclonal-antibody lymphocyte typing techniques, we were able to select two CLL cases in one of which the peripheral blood lymphocytes comprised 0% T-cells, 85% B-cells (case Z72, leukocytes 60 x 103/L) and in the other 77% T-cells, 0% B-cells (Z15, leukocytes 149.6 x 103/giL). Careful analysis of these samples ( Figure 2 , Table 1 ) showed quantitative differences between the T and B leukemias in 29 proteins, which also differ significantly between normal T and B cells isolated by use of monoclonal antibodies and fluorescence-activated cell sorting (K. E. Willard-Gallo and M. Loken, manuscript in preparation).
For 27 of these 29 proteins, the differences between leukemic T and B cells were in the same sense (i.e., increase or decrease) as those between normal T vs B cells ( Table 1 ). The exceptions were Mitcon:4 (same as T:12 in Table 1 ), a mitochondrially encoded protein whose expression is affected by various influences, including intracellular calcium and heat shock, and a minor phosphoprotein about which little is known (B:9, square in Figure 2 ). One of the principal markers showing consistently large T-B differences in both normal and leukemic cells is the LDH-B chain (circle numbered 1 in Figure 2B) ; B-cells appear to produce less of this polypeptide than do T-cells. The T-CLL has the unusual feature (for a lymphocyte) of producing large amounts of the polypeptides labeled Q:2 ( Figure 2B ), which appear to be involved in phagocytosis and are usually characteristic of monocytes, granulocytes, or fibroblasts.
Less Well-Differentiated Leukemias
Analysis in terms of cell-type specific markers is more difficult for leukemias that appear to involve proliferation of immature leukocyte precursors.
An acute granulocytic leukemia (FAB classification M1; Z77, Figure 1B) showed only very low amounts of most granulocyte or monocyte markers. However, a greatly increased amount of a novel protein (Q:3) appears; this protein may be characteristic of an early myeloid precursor, because it is also expressed by the promyelocytic leukemic cell line HL-60 under some conditions. The monocyte/granulocyte specific mitochondrial protein Mitcon:5 (labeled in Figure 1C ) is also more greatly expressed than would be expected in the absence of other monocyte or granulocyte markers.
A case of acute undifferentiated leukemia (Z74; Figure  1D ) also shows a lack of mature monocyte or granulocyte markers (this time including a lack of Mitcon:5), but shows large amounts of several new proteins exemplified by Q:8. #{149} a -.
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Both Z90 and Z105 express a set of proteins (Q:7) that also appear in some promyelocytic leukemias, an acute monocytic leukemia (Z41; Figure 1C ), and to a lesser extent in an acute undifferentiated leukemia (Z74, Figure 1D ). The Q:7 set is not found in normal lymphocytes, monocytes, or granulocytes.
Discussion
The results presented here are intended to elucidate two principal questions: (a) have led to the identification of a panel of 30 proteins that differ quantitatively between normal human T and B lymphocytes. Using this panel, we have examined the fidelity of almost pure T-and B-cell CLL's to the phenotypic patterns of their normal counterparts. The cases we used to represent T and B CLL's were characterized by high leukocyte counts (60 and 150 x i03/ zL, respectively). The leukocytes consisted mainly of lymphocytes (lymphocytes + atypical lymphocytes represented 92.5 and 98%, respectively), indicating a large preponderance of leukemic cells, and showed very high type-specificity, as determined by staining with enzyme-labeled monoclonal antibodies (77% T + 0% B and 0% T + 85% B, respectively). Of the 29 T and B markers we could unequivocally identify in the leukemic cell patterns, 27 differed quantitatively in the same sense (by increase or decrease) as
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--'1 These results make it appear quite likely that monocytic leukemias ( Figure 1C and Figure 3A (B:l-3, which may comprise part of the DR antigen, and a few of the others being possible exceptions). Most occur in other leukocyte types as well, suggesting that particular cell subtypes may be defined more by patterns of gene expression than by a few unique proteins. Although a large panel of both T and B leukemias will be needed to confirm the reliability of individual markers, it seems highly likely that panels such as we have used can distinguish T and B leukemias without recourse to antibody staining.
Only one of the proteins in the T vs B panel we used has yet been identified as a previously known marker; T:1 (Figure 2 ) is the LDH-B polypeptide that, when expressed alone, gives rise to the LDH-1 phenotype.
The LDH-A isoenzyme has not yet been identified in the two-dimensional pattern, and may have an isoelectric point too basic to appear on these gels. Additional groups of proteins may have significance in the leukemias, even though they can also be detected elsewhere. The set marked Q:7 IFigure 3, acute monocytic and granulocytic leukemias, also occurring in acute monocytic leukemia Z41 ( Figure 1C) , and to some extent in acute undifferentiated leukemia Z74 ( Figure 1D )1 can be induced in normal lymphocytes under some stressful conditions, but it seems never to occur in normal lymphocytes that have been handled like the leukemic cells in this study (they do not occur in our parallel control samples, for instance). The main spots of Q:7 show striking similarities to the non-muscle myosin light chains (MLC) near which they are situated; possibly they represent expression of a set of normally repressed MLC genes. The Metmin spots (Figure 3B) include three apparently different proteins that are induced in some cells during culture in methionine-free medium. Metmin:2 and -3 in particular seem to be substantially expressed only in one acute granulocytic leukemia (Z105) and the acute undifferentiated leukemia (Z74) examined in this study. Other work (N. L. Anderson teins (18, 19) . Here we have shown that the limited knowledge we have so far concerning differences among cell types
and among subtypes appears to be directly applicable to the typing of some leukemias (as in CLL). As this knowledge is expanded its usefulness in diagnostic typing will probably increase. In addition, the observation of novel proteins, particularly in the acute leukemias, may provide markers capable of further dissecting the pathways of leukocyte differentiation.
As the function of such marker proteins are elucidated, new targets for therapeutic agents may be discovered.
